ACTA NEUROPHARMACOLOGICA ›› 2024, Vol. 14 ›› Issue (6): 58-.DOI: 10.3969/j.issn.2095-1396.2024.06.009

Previous Articles    

Progress in the Use of Oral Chemotherapeutic Agent Xeloda

JIA Xiao-kun   

  1. The Department of Body Collection, Zhangjiakou Central Blood Station, Zhangjiakou, 075000, China
  • Online:2024-12-26 Published:2024-12-26

Abstract:

Xeloda, also known as capecitabine tablets, is the first oral fluorouracil chemotherapy drug, which is converted into 5-fluorouracil(5-FU) by intestinal absorption, and 5-FU is converted into deoxyuridylate monophosphate (FdUMP) and 5-fluoruridylate triphosphate (FUTP) by cell metabolism. It can well simulate the state of 5-FU intravenous therapy, with high effectiveness. Convenience and high efficiency are often used in adjuvant therapy, combined with paclitaxel and other drugs to treat breast cancer, gastric cancer and other diseases, but there are still many adverse reactions. This article reviews the structure, function, clinical application and clinical effect of oral chemotherapy Xeloda.

Key words: Xeloda, capecitabine, pharmacological effects, pharmacokinetics, clinical application

CLC Number: